IGF1R and non-small cell lung carcinoma: Figi-tumumab, a monoclonal antibody against IGF-IR, was developed in 2011 for the treatment of various types of cancer, e.g., adrenocortical carcinoma [216] non-small cell lung cancer (NSCLC) [217], but further development was terminated due to severe adverse effects [218].